Century Therapeutics (IPSC) Operating Margin (2022 - 2025)
Historic Operating Margin for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to 67.95%.
- Century Therapeutics' Operating Margin rose 37298200.0% to 67.95% in Q1 2025 from the same period last year, while for Sep 2025 it was 29.91%, marking a year-over-year increase of 53561300.0%. This contributed to the annual value of 2096.48% for FY2024, which is 44603900.0% up from last year.
- Latest data reveals that Century Therapeutics reported Operating Margin of 67.95% as of Q1 2025, which was up 37298200.0% from 893.46% recorded in Q4 2024.
- Century Therapeutics' 5-year Operating Margin high stood at 67.95% for Q1 2025, and its period low was 35431.31% during Q2 2023.
- In the last 4 years, Century Therapeutics' Operating Margin had a median value of 3661.87% in 2024 and averaged 8053.42%.
- Its Operating Margin has fluctuated over the past 5 years, first crashed by -331855400bps in 2023, then soared by 309235300bps in 2024.
- Century Therapeutics' Operating Margin (Quarter) stood at 6392.71% in 2022, then tumbled by -155bps to 16329.1% in 2023, then soared by 95bps to 893.46% in 2024, then skyrocketed by 108bps to 67.95% in 2025.
- Its Operating Margin was 67.95% in Q1 2025, compared to 893.46% in Q4 2024 and 4398.1% in Q3 2024.